Cabazitaxel
| CAS No. | 183133-96-2 | Cat. No. | BCP27641 |
| Name | Cabazitaxel | ||
| Synonyms | XRP6258; XRP-6258; XRP 6258; TXD 258; TXD-258; TXD258; | ||
| Formula | C45H57NO14 | M. Wt | 835.93 |
| Description | Cabazitaxel increases CYP3A enzyme activities in rat hepatocytes. The mean ex-vivo human plasma protein binding of Cabazitaxel is 91.6%. Cabazitaxel is rapidly and extensively metabolised in numerous metabolites. Cabazitaxel demonstrates activity in several murine and human resistant cell lines.With a 4-day exposure to cabazitaxel, cytotoxicity is noted with relatively low cabazitaxel concentrations. Cabazitaxel shows high antitumor activity in 3 human colorectal cell lines (HCT-116, HCT-8, and HT-29). | ||
| Pathways | Ion Channel/Membrane Transporter Neuro Signaling Pathway Cell Cycle/DNA Damage | ||
| Targets | P glycoprotein Microtubule | ||
|
Subcellular detection of PEBCA particles in macrophages: combining darkfield microscopy, confocal Raman microscopy, and ToF–SIMS analysis
Publications Citing of Biochempartner's Cabazitaxel(CAS:183133-96-2) |
|
A comparative biodistribution study of polymeric and lipid-based nanoparticles
Publications Citing of Biochempartner's Cabazitaxel(CAS:183133-96-2) |
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.